Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to ... praised the donation as a sign of progress in public-private partnerships. “I am honored to work alongside Pfizer and ...

Pfizer’s effective tax rate on Reported (2) income for the first quarter of 2025 is negative, primarily due to favorable global income tax resolutions in multiple tax jurisdictions spanning ...